Tirzepatide vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Also: GSBR-1290, Structure GSBR-1290
A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Key Comparison Insights
- Tirzepatide is FDA approved, while Eloralintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Tirzepatide has stronger research evidence (FDA Approved) compared to Eloralintide (Phase 2 Clinical Trial).
Detailed Comparison
| Attribute | Tirzepatide | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying. | Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. |
| Common Dosing | 5-15 mg weekly (after titration) Once weekly | 120-240mg once daily (oral) Once daily |
| Administration | Subcutaneous injection weekly | Oral tablet |
| Typical Duration | Long-term / chronic use | 36 weeks in Phase 2 trials |
| Best Time to Take | Morning, same day each week | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | SURMOUNT trials showed average weight loss of 20-26% body weight. SURMOUNT-OSA showed 25-29 fewer sleep apnea events per hour. SURPASS-2 showed superior A1C reduction compared to semaglutide. SUMMIT trial (2024-25) showed 38% reduction in CV death or worsening heart failure in HFpEF patients with obesity - data added to EU labeling Jan 2026. | Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts. |
Frequently Asked Questions: Tirzepatide vs Eloralintide
What is the difference between Tirzepatide and Eloralintide?
Tirzepatide is a weight loss peptide that a dual gip/glp-1 receptor agonist representing the next generation of incretin-based therapies. shows superior weight loss compared to semaglutide in head-to-head trials. first medication approved for obstructive sleep apnea. Eloralintide is a weight loss peptide that a next-generation oral glp-1 receptor agonist developed by structure therapeutics (now ventyx biosciences). shows comparable weight loss to injectable glp-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tirzepatide or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. Tirzepatide is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tirzepatide and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tirzepatide and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.